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Abstract:  Retroviruses undergo several critical steps to complete a replication cycle. 
These include the complex processes of virus entry, assembly, and budding that often take 
place at the plasma membrane of the host cell. Both virus entry and release involve 
membrane fusion/fission reactions between the viral envelopes and host cell membranes. 
Accumulating evidence indicates important roles for lipids and lipid microdomains in virus 
entry and egress. In this review, we outline the current understanding of the role of lipids 
and membrane microdomains in retroviral replication. 
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1. Introduction 
Retroviruses comprise a diverse group of enveloped RNA viruses that cause a variety of diseases, 
prominent among these are acquired immunodeficiency syndrome (AIDS) and various types of 
cancers. Retroviruses replicate via the enzyme reverse transcriptase (RT), which produces a linear 
double-stranded DNA copy of the genomic RNA after entry into the host cell. The newly synthesized 
viral DNA is then integrated into the genome of the host cell and is replicated as part of the host cell 
DNA. Retroviruses are classified based on their structure, composition, and replication properties. 
Retroviral particles are ~80-120 nm in diameter and their lipid envelope incorporates the viral 
OPEN ACCESSViruses 2010, 2                               
         
 
1147
envelope (Env) glycoproteins that recognize receptors on host cells. Retroviruses encapsidate two 
identical, linear single-stranded RNA molecules of 7-13 kb in length. Three genes are encoded by the 
genomes of all replication-competent retroviruses. The gag gene encodes the Gag polyprotein 
precursor, which contains matrix (MA), capsid (CA) and nucleocapsid (NC) domains. For most 
retroviruses, the pol gene encodes the viral protease (PR), RT, and integrase (IN). The env gene 
encodes the surface (SU) and transmembrane (TM) components of the viral Env glycoprotein 
complex. 
Retroviral replication is a multi-step process, with viral entry and budding constituting the two steps 
that are intimately associated with host cell membranes. Retroviruses enter susceptible target cells by 
Env-mediated fusion between the viral envelope and the target cell plasma membrane or in low-pH 
endosomes following endocytic uptake of virions bound to the cell surface. In most cases, virus 
budding takes place at the plasma membrane of the infected cell and particle release requires a 
membrane fission, or “pinching-off” reaction whereby the viral and cellular membrane separate. It is 
well documented that lipids in both the viral and cellular membrane play an important role in retroviral 
replication; these lipids include cholesterol, sphingolipids and certain phospholipids. In addition to 
cholesterol and sphingolipids, phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] also serves an 
important function in viral assembly and release. Studies published over the past decade have provided 
evidence that cholesterol- and sphingolipid-enriched microdomains in the plasma membrane, known as  
“lipid rafts”, are involved in both entry and egress of viral particles. In two previous reviews [1,2], we 
discussed the role of lipid rafts in the replication of both enveloped and non-enveloped viruses. The 
latter review focused in particular on lipids and membrane microdomains in HIV-1 replication. In this 
review, we discuss more generally the role of lipids in retroviral replication and provide an update on 
recent developments in this field. 
2. Retrovirus classification 
Based on their genome organization, retroviruses are informally grouped into two categories: simple 
and complex. In addition to gag, pol  and en v genes that are present in the genomes of simple 
retroviruses, complex retroviruses encode a diversity of additional proteins. For example, HIV-1 
encodes six additional regulatory and accessory proteins, some of which (Vif, Vpr, and Nef) are 
incorporated in the viral particles and others (Tat, Rev, and Vpu) are not associated with virions 
(Figure 1). Retroviruses are more formally classified into seven genera based on genome complexity 
and virion morphology. These genera of the Retroviridae include the alpharetroviruses, 
betaretroviruses, gammaretroviruses, deltaretroviruses, epsilonretroviruses, lentiviruses, and 
spumaviruses. The first three genera are simple retroviruses, whereas the deltaretroviruses, 
epsilonretroviruses, lentiviruses, and spumaviruses are complex. The virions of alpha-, gamma-, and 
deltaretroviruses have a central, spherical core, whereas betaretroviruses have an acentric spherical or 
cylindrical core. Lentiviruses contain cone-shaped cores while spumaviruses have spherical cores. 
Some notable examples in each genus include: the alpharetrovirus Rous sarcoma virus (RSV); 
betaretroviruses mouse mammary tumor virus (MMTV), Jaagsiekte sheep retrovirus (JRSV), and 
simian
 type D retrovirus (SRV); the gammaretroviruses murine leukemia virus (MLV), feline leukemia 
virus (FeLV), and gibbon ape leukemia virus (GALV); the deltaretroviruses bovine leukemia virus Viruses 2010, 2                               
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(BLV) and human T-lymphotrophic virus (HTLV); and epsilonretroviruses walleye dermal sarcoma 
virus (WDSV) and snakehead retrovirus (SnRV). The lentivirus genus includes human 
immunodeficiency viruses (HIV-1 and HIV-2), simian immunodeficiency virus (SIV), feline 
immunodeficiency virus (FIV), and equine infectious anemia virus (EIAV). Examples of spumaviruses 
include feline foamy virus (FFV), bovine foamy virus (BFV) and simian foamy virus (SFV).  
Figure 1. Genomic organization of HIV-1. The rectangles indicate the open reading frames 
for the gag (brown), pol (yellow), and env (blue) genes. Complex retroviruses like HIV-1 
encode additional regulatory and accessory genes (shown in pink). Tat and Rev introns are 
depicted as horizontal lines. The major Gag domains matrix (MA), capsid (CA), 
nucleocapsid (NC), and p6 and the Env surface (SU) and transmembrane (TM) 
glycoproteins (gp120 and gp41, respectively, in the case of HIV-1) are indicated. The 5’ 
and 3’ long terminal repeats (LTRs) are also shown. 
 
 
3. Retrovirus replication 
Retrovirus replication generally occurs in the following series of steps (Figure 2) [3]: (1) The 
infection process begins when the SU subunit of the Env glycoprotein complex interacts with its 
receptor(s) on the target cell. For example, CD4 serves as the major receptor for HIV-1, and the 
chemokine receptors CCR5 and CXCR4 serve as “co-receptors”. Cell tropism is often determined by 
the receptor specificity of the Env glycoprotein. In the case of MLV, for instance, ecotropic viruses 
infect only mouse cells, xenotropic viruses target non-mouse cells, and amphotropic strains infect both 
mouse and non-mouse cells. (2) Receptor binding induces conformational changes in the Env 
glycoprotein complex, resulting in exposure of the fusion peptide of the TM protein and its insertion 
into the target cell membrane. Fusion peptide insertion leads to the fusion of the viral and host cell 
lipid bilayers. This most often occurs at the plasma membrane but in some cases can take place in a 
low-pH endosomal compartment. Virion-cell membrane fusion results in the release of the viral core 
into the cytoplasm of the host cell. (3) In the cytosol of the target cell, the virion core is uncoated and 
(4) the incoming viral RNA is reverse transcribed by the RT enzyme into a double-stranded DNA 
copy. (5) The newly synthesized viral DNA, protected within a high-molecular weight “preintegration Viruses 2010, 2                               
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complex” (PIC), translocates to the nucleus. (6) Once the PIC is inside the nucleus, the viral enzyme 
IN catalyzes the integration of the viral DNA into the host cell chromosome. (7) The integrated 
proviral DNA is transcribed into the viral RNAs from the promotor located in the 5’-long terminal 
repeat (LTR). (8) The viral mRNAs and full-length genomic RNAs are transported from the nucleus to 
the cytoplasm. (9) The viral RNAs are translated in the cytoplasm and the Gag and GagPol polyprotein 
precursors traffic to the plasma membrane by poorly understood pathway(s). (10) The Env 
glycoproteins are translated in the endoplasmic reticulum (ER) and are transported to the plasma 
membrane via the secretory pathway. (11) Membrane-targeted Gag and GagPol polyproteins recruit 
the genomic RNAs and assemble at the plasma membrane, leading to the induction of membrane 
curvature at the site of assembly. For some genera of retroviruses, assembly occurs in the cytosol in the 
absence of membrane association (e.g., the betaretroviruses) or in the ER (e.g., the spumaviruses).  
(12) The Env glycoproteins are incorporated into the budding particles during the assembly process. 
(13) The budding virions wrap themselves in the host cell plasma membrane and pinch off from the 
surface of the infected cell. Virus budding and release are mediated by the hijacking of cellular 
endosomal sorting machinery, which normally functions in the sorting of cargo proteins and the 
budding of vesicles into multivesicular bodies (MVBs). (14) The released virions undergo 
morphological changes known as maturation, which takes place during or after budding. The 
maturation process involves viral PR-mediated cleavage of the Gag and GagPol precursors in the 
virion. With maturation, the viral replication cycle is complete, and the newly released virions can 
initiate a new round of infection.  
Figure 2. Schematic representation of the HIV-1 replication cycle. The steps that comprise 
the replication cycle are described in more detail in the text. Reprinted with permission 
from Freed [221]. Copyright 2004 Elsevier Inc. 
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4. Lipids in cell and viral membranes 
4.1. Composition of cell membranes 
The major structural lipids in mammalian cell membranes are glycerophospholipids (GPLs), 
sphingolipids, and sterols [2,4-6]. All cellular membranes contain GPLs, and based on the head group 
attached via glycerol to two acyl chains, GPLs are classified into several types. These include 
phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidic acid 
(PA), and phosphatidylinositol (PI). The hydrophobic portion of GPLs is a diacylglycerol (DAG) 
moiety that contains saturated or cis-unsaturated fatty acyl chains of varying lengths (Figure 3). PC is 
the major lipid in mammalian cell membranes, accounting for ~50% of the total phospholipid content. 
Most PC molecules have one cis-unsaturated fatty acyl chain. PE, the second most abundant GPL in 
cell membranes, imposes membrane curvature due to its small polar head group. This curvature helps 
in budding, fission and fusion of cell membranes [7]. Although GPLs are sufficient to form bilayers, 
most mammalian cells also contain sphingolipids and sterols. Sphingolipids contain a hydrophobic 
ceramide (Cer) backbone. The major sphingolipids in mammalian cells are sphingomyelin (SM) and 
glycosphingolipids (GSLs) that differ in their head group. SM contains a phosphatidylcholine head 
group, whereas GSLs contain a carbohydrate moiety. Depending on the specific carbohydrate 
modification, GSLs are further classified into several types, e.g., glucosylceramide (GlcCer) and 
galactosylceramide (GalCer). Gangliosides are one type of GSLs in which one or more sialic acids are 
linked to the sugar chain. Sphingolipids in general have saturated (or trans-unsaturated) acyl chains, 
causing them to form long, narrow structures that pack more tightly than GPLs, resulting in a solid gel 
phase. Sterols are the major non-polar lipids in cell membranes, and cholesterol is the principle sterol 
in mammalian cell membranes. Sphingolipids and sterols are present at low levels in intracellular 
membranes compared to the plasma and endosomal membranes [6,8,9]. Sphingolipids are synthesized 
in the Golgi apparatus, whereas glycerophospholipids and sterols are made in the ER.  
The cellular lipidome is made up of a large number of glycerophospholipids, sphingolipids, and 
sterol-derived molecules [10,11]. Lipid composition varies between cell types, and lipids in the plasma 
membrane are distinct from those located in intracellular membranes, and among intracellular 
membranes the composition differs depending on the organelle. The major lipids in mammalian cell 
membranes are PC, PE, PS, PA, PI, SM, and cholesterol [6,12,13]. Most sphingolipids and PC are 
distributed predominantly in the outer leaflet of the membrane, whereas PE, PS, and PI are primarily in 
the inner leaflet [14]. Cholesterol is present in both leaflets and spontaneously flips between the two 
leaflets [15]. Due to the stronger interactions of cholesterol with sphingolipids and tight packing of 
highly saturated sphingolipid acyl chains, phase separation occurs in the membranes, resulting in the 
formation of a liquid-ordered (lo) phase [16,17]. Phospholipids are rich in kinked, unsaturated acyl 
chains and exhibit weaker interactions with cholesterol, resulting in a loosely packed liquid-disordered 
(ld) phase [16,17]. Thus, cholesterol plays an important role in regulating phase behavior, with the lo 
phase favored at high concentrations [5,17,18].  Viruses 2010, 2                               
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Figure 3. Structures of major classes of lipids in eukaryotic cells. Glycerophospholipids 
contain diacylglycerol, a phosphate group, and a simple organic head group. The acyl 
chains contain 16-18 carbon atoms and one of the acyl chains is generally unsaturated with 
a  cis double bond. The head groups vary among the phospholipids; e.g., choline in 
phosphatidylcholine (PC), ethanolamine in phosphatidylethanolamine (PE), serine in 
phosphatidylserine (PS), and inositol in phosphatidylinositol (PI). Sphingolipids are based 
on ceramide, which has long saturated acyl chains of 16-26 carbon atoms, and either 
phosphorylcholine (sphingomyelin) or sugar (glycosphingolipids) headgroups. Depending 
on the type of sugar, glycosphingolipids are further sub-classified into several types as 
listed in the figure. Cholesterol is a major sterol in mammalian cells.  
 
 
Due to the enrichment of sphingolipids in the outer leaflet of the plasma membrane, clustering of 
sphingolipids and cholesterol occurs, resulting in a lo domain that “floats” in the surrounding ld 
domains. These floating microdomains have been termed lipid rafts (Figure 4) [19-21]. Lipid rafts can 
be biochemically isolated as detergent-resistant membrane (DRM) at low temperatures due to their 
insolubility in nonionic detergents like Triton X-100 [22]. DRM complexes float to a low density in 
sucrose gradients because of their high lipid content [17,18]. Although the DRM approach for isolating 
lipid rafts has major shortcomings – e.g., DRMs are aggregates of raft domains that are formed after 
cell lysis [4] – this approach is still commonly used to identify raft-associated proteins [17,18]. To Viruses 2010, 2                               
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overcome the limitation of DRM-based assays, immunofluorescence microscopy methods that 
visualize copatching of a protein of interest with well-known raft markers (e.g., GM1) can be coupled 
with DRM methods to identify protein association with lipid rafts [23,24]. Lipid rafts, or more 
generally cholesterol-enriched membrane microdomains, have been visualized in living cells by using 
advanced microscopic approaches including fluorescence resonance energy transfer (FRET), 
fluorescence recovery after photobleaching (FRAP), single-particle tracking (SPT), two-photon 
microscopy, and immunoelectron microscopy (IEM) [23,25-32]. 
Figure 4. A simplified model of lipid rafts in cell membranes. The phospholipids (blue and 
brown) and cholesterol (yellow) are distributed in both the leaflets, whereas sphingolipids 
(violet) are enriched in the outer leaflet of the bilayer. The acyl chains of raft lipids are 
generally long and saturated (violet and brown), whereas those in non-raft domains are 
shorter and contain singly or multiply unsaturated acyl chains (blue). Raft domains contain 
concentrations of dually-acylated (green) and GPI-anchored (brown) proteins, whereas 
transmembrane (blue) and prenylated (green) proteins are usually non-raft associated. 
Reprinted with permission from Waheed and Freed [2]. Copyright 2009. Elsevier Inc. 
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4.2. Composition of viral membranes 
Enveloped viruses acquire their lipid bilayers from host-derived membranes. The origin of the viral 
membrane depends on the site of virus assembly and budding. For the majority of retroviruses, the 
plasma membrane is the primary site of membrane envelopment. Interestingly, the lipid composition of 
viral lipid bilayers is often significantly different from that of the host cell membrane from which the 
viral envelope is derived. Indeed, it was this observation that first suggested the possibility that 
enveloped viruses assemble in distinct membrane microdomains [33-35]. For example, the lipidome of 
retroviral membranes is strikingly different from that of the host cell plasma membrane [36-38].   
PC, the major phospholipid in mammalian plasma membranes, is reduced by about two-fold [37,38]. 
PE in the HIV-1 membrane was shown to be reduced relative to the host cell plasma membrane by 
two-fold in one study [37] but enriched by 1.6-fold in another report [38]. The lipids that are enriched 
in viral membranes compared to host cell membranes are SMs (~2-3 fold), PS (~2-3 fold), and 
plasmalogen PE (pl-PE) (~2 fold) [37,38]. Cholesterol is also enriched in the viral membrane by a 
factor of ~2 in virions [36-38]. Cer was observed to be reduced in virions by over three-fold [37,38]. 
Overall, the HIV membrane is reportedly enriched in saturated PCs by ~3.6-fold compared with the 
cell membrane. This enrichment is counter-balanced by a ~2.5-fold reduction in diunsaturated and 
polyunsaturated PCs [37]. Interestingly, phosphatidylinositol monophosphate (PIP) and PI(4,5)P2 are 
enriched in the HIV-1 membrane by 1.6-fold compared to the plasma membrane [38], supporting a 
role for PI(4,5)P2 in virus assembly (see below). Significantly, the lipid composition of the HIV-1 
membrane is very similar to that of DRMs [37], suggesting that HIV-1 membranes are derived from 
cholesterol-enriched lipid rafts. The lipidome of the gammaretrovirus MLV was also reported by 
Wenk and co-workers to contain a higher ratio of cholesterol (two-fold), dhSM (1.8-fold),   
Cer (2.2-fold), GM3 (2.9-fold), PIP (4.7-fold), and PI(4,5)P2 (10.4-fold) compared to the plasma 
membrane of the producer cells [38]. Again, these studies indicate that the lipid composition of the 
viral envelope is distinct from that of the plasma membrane, but similar to that of lipid rafts, 
suggesting that these retroviruses bud from cholesterol-enriched plasma membrane microdomains.  
5. Lipids in retrovirus replication 
5.1. Lipids in retrovirus entry 
The entry of retroviruses into their target cells is initiated by interactions between viral Env 
glycoproteins embedded in the lipid bilayer of the virion and specific cell-surface receptors. After 
attachment to their cellular receptor(s), retroviruses can enter cells by direct fusion at the plasma 
membrane or by receptor-mediated endocytosis of the virus particle followed by fusion between viral 
and endosomal membrane. The fusion process is initiated by conformational changes in Env that result 
in exposure of a hydrophobic fusion peptide at or near the N-terminus of the TM subunit and two 
heptad repeats downstream of the fusion peptide [3,39]. Fusion of viral and cell membranes is required 
for the penetration of the viral core into the host cell cytoplasm. Lipids and lipid microdomains on the 
plasma membrane of the host cell and on the viral membrane play an important role in viral entry. The 
function of specific lipids in viral entry is discussed in detail below. Viruses 2010, 2                               
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5.1.1. Role of cholesterol in retrovirus entry 
As discussed earlier, the lipid bilayers of many retroviruses are enriched in cholesterol, which 
supports their genesis in lipid raft microdomains [36-38]. This cholesterol enrichment appears to be 
important for viral infectivity. Depleting cholesterol from virions with ß-cyclodextrin (BCD) 
significantly inhibits the infectivity of HIV-1 virions [40-43]. A limitation of cholesterol depletion 
approaches is that removal of the majority of cholesterol from HIV-1 virions results in loss of viral 
components due to the formation of holes in the viral lipid bilayer [41]. However, modest depletion of 
cholesterol using milder cholesterol sequestering agents such as 2-hydroxypropyl-ß-cyclodextrin 
(2OHpßCD) does not cause substantial loss of viral proteins, but infectivity is still markedly reduced 
[40-43]. In this context, replenishment of cholesterol restores the infectivity of HIV-1 indicating that 
the virions were not completely disrupted after modest removal of cholesterol [40-43]. The effects of 
cholesterol depletion on virion density were also reversed by cholesterol replenishment [40]. 
Interestingly, replenishment with the cholesterol analog cholestenone reverses the shift in density 
induced by cholesterol depletion but does not restore virus infectivity [40]. The infectivity of   
VSV-G-pseudotyped HIV-1 virions was less susceptible to cholesterol depletion than the infectivity of 
virions bearing the native HIV-1 Env glycoproteins, suggesting that this sterol is critical for receptor-
mediated HIV-1 entry [42]. Furthermore, a number of studies found that HIV-1 particles produced 
from cholesterol-depleted cells were poorly infectious compared to those produced from normal cells 
[44-46]. Because virions bud from cholesterol-rich microdomains, cholesterol depletion results in a 
reduced amount of cholesterol on the viral membrane, which in turn inhibits viral infectivity. 
Cholesterol-chelating compounds like nystatin have also been reported to inhibit HIV-1 infectivity 
[42,47]. Recently, we have shown that the cholesterol-binding compound amphotericin B methyl ester 
(AME), a water-soluble derivative of amphotericin B, inhibits HIV-1 entry [48-51]. 
Depletion of cholesterol from the target cell inhibits viral fusion and entry, resulting in impaired 
infectivity [41,52-55]. This inhibition could be due to perturbation of lipid rafts, resulting in 
dissociation of CD4 or co-receptors from these microdomains. It was reported that both CD4 and 
CCR5 are associated with lipid rafts [55,56], and that a CD4 mutant that is defective in raft association 
is unable to support HIV-1 infection in CD4
+ T-cells [57]. However, studies from other groups 
suggested that HIV-1 entry is not dependent on the raft localization of CD4 or CCR5 [58,59]. It has 
been suggested that CXCR4, although normally not raft-associated, is recruited into raft aggregates 
after gp120 binding [55]. Interestingly, the inhibitory effects of cholesterol depletion can be overcome 
by coreceptor overexpression [60]. It has also been reported that a highly conserved motif, LWYIK, 
located near the N-terminus of the membrane-spanning domain of gp41, binds to cholesterol and that 
mutations in this domain inhibit HIV-1 infectivity [61-63]. In addition to acute cholesterol depletion 
with cyclodextrins, an alternative approach to limiting the formation of lipid rafts is to inhibit 
cholesterol biosynthesis using statin drugs, which target the enzyme 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA). For example, lovastatin treatment of macrophages significantly inhibits 
productive HIV-1 entry [64]. Further, drugs like nystatin and filipin that modify the cholesterol 
organization within cells without affecting overall cholesterol concentration also inhibit HIV-1 entry 
into macrophages [64]. The impairment of entry is correlated with the reduction in cell surface 
expression of CD4 and CCR5 [64]. This suggests that, at least in macrophages, cholesterol could Viruses 2010, 2                               
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potentially enhance the ability of the gp120-gp41 complex to cluster CD4 and coreceptors during the 
initiation of fusion. 
Cholesterol and caveolae – flask-shaped invaginations in the plasma membrane that are categorized 
as a special type of lipid raft microdomain [65] – have also been implicated in MLV infection. The 
entry of amphotropic MLV was initially thought to occur directly at the plasma membrane, whereas in 
most cell types ectotropic MLV was reported to enter by pH-dependent fusion after endosomal uptake 
[66,67]. However, more recent studies show that amphotrophic MLV also enters target cells through 
caveolae-mediated endocytosis via its receptor Pit2 [68,69]. Beer et al. also found a direct association 
of Pit2 with caveolin, the protein component of caveolae, as demonstrated by coimmunoprecipitation 
and inhibition of amphotropic MLV infection by dominant-negative caveolin-1 [68]. The receptor for 
ectotropic MLV is the cationic amino acid transporter 1 (CAT1), and, based on its colocalization with 
caveolin, is thought to be associated with caveolae [66,70]. CAT1 is also detected in DRM fractions 
[71]. It has been reported that depleting cholesterol from target cells that express endogenous or   
over-expressed CAT-1 resulted in inhibition of MLV entry [71,72]. These studies indicate that 
cholesterol plays an important role in caveolae-mediated endocytosis of MLV. 
There is a considerable amount of evidence to support the hypothesis that HTLV-1 entry is 
dependent on cholesterol-rich domains. Niyogi and Hildreth reported that monoclonal antibodies that 
bind to raft-associated proteins, including several GPI-anchored proteins, inhibit HTLV-1-induced 
syncytium formation [73]. Depletion of cellular cholesterol with BCD inhibited syncytium formation 
[73] and binding of HTLV-1 virions to T cells [74]. Two of the reported HTLV receptors, GLUT-1 
and neuropilin-1, have been shown to colocalize with raft-associated markers and to cluster in specific 
membrane microdomains [75,76]. Cholesterol-depletion experiments suggest that cholesterol promotes 
efficient HTLV entry into target cells without affecting receptor binding [76]. These studies support 
the importance of cholesterol and raft-associated receptors in HTLV-1 entry.  
The importance of cholesterol has also been demonstrated for other retroviruses. For EIAV, BCD 
treatment of the virion but not the target cell interferes with viral infectivity [77]. SIV infectivity is 
also susceptible to cholesterol depletion [41]. Finally, we have shown that the cholesterol-binding 
compound AME inhibits the infectivity of SIV by more than 20-fold, similar to its effect on   
HIV-1 [49-50]. 
5.1.2. Role of sphingolipids in retrovirus entry 
Sphingolipids, like cholesterol, are an important constituent of lipid rafts, and have also been 
reported to play an important role in viral entry. Several lines of evidence suggest that GSLs in the cell 
membrane serve to promote HIV-1 binding. It was reported that the V3 loop of gp120 interacts with 
galactoceramide (GalCer) to facilitate infection of cells lacking CD4 [78-82]. Yahi et al. reported that 
a synthetic peptide derived from the V3 loop consensus motif (GPGRAF) inhibited HIV-1 infection 
both in CD4-negative and CD4-positive cells [83].  Synthetic soluble analogs of GalCer, and   
anti-GalCer antibodies, reportedly inhibit HIV-1 entry when present during infection [80,82,84]. 
Hammache et al. demonstrated specific interactions of HIV-1 and HIV-2 Env glycoproteins with GSLs 
GalCer, GM3, and globotriaosylceramide (Gb3) [81]. A similar study showed preferential interactions 
of gp120 from CXCR4- and CCR5-tropic viruses with Gb3 and GM3, respectively [85]. Several Viruses 2010, 2                               
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studies suggest that besides GM3, GM1 also functions as a cofactor for HIV-1 Env-mediated fusion 
[81,86-89]. Interestingly, reconstitution of GSLs such as GM3 and Gb3 in GSL-depleted GM95 cells 
restored HIV-1 Env-mediated fusion [88,90]. The galactosyl ceramide/sulfatide was shown to bind 
directly to gp120 [78,79]. Pretreating CD4
+ cells with compounds that inhibit GSL synthesis has a 
significant effect on HIV-1 fusion [88]. The requirement for GSLs in target cells for promoting entry 
could not be rescued by overexpression of CD4 or coreceptors [87]. Nguyen and Taub showed that  
co-treatment of target cells with sphingomyelinase (SMase) and cholesterol oxidase reduced HIV-1 
infectivity by several fold [91]. SMase treatment of target cells restricted the lateral diffusion of CD4 
and inhibited HIV-1 fusion [92]. The upregulation of ceramide, a by-product of SMase treatment, 
significantly reduced HIV-1 infectivity in CD4
+ lymphocytes and in monocyte-derived macrophages 
without overt toxicity [93]. Thus, GSLs may potentially enhance HIV-1 Env-mediated fusion by 
serving as direct binding sites for Env on the cell surface [89,94]. Furthermore, GSLs may promote the 
clustering of CD4 and coreceptors in specific domains and regulate their mobility in the target cell 
membrane, perhaps promoting HIV-1 entry by stabilizing fusion intermediates [89]. In contrast, 
CD4
+/coreceptor
+ derivatives of a mouse melanoma cell line (B16) that expresses exceptionally high 
levels of GM3 [95] were resistant to CD4-dependent fusion [96]. Interestingly, this block was rescued 
by pretreating the target cells with GSL inhibitors such as 1-phenyl-2-palmitoylamino-3-morpholino-
1-propanol (PPMP); recovery of fusion correlated with downregulation of GM3 to normal levels [96]. 
The authors proposed that the elevated expression of GM3 in B16 cells could restrict the mobility of 
CD4 and/or chemokine receptors, thereby blocking the interactions between the different cell surface 
receptors required for fusion [96]. These observations suggest that GSLs can enhance or inhibit HIV-1 
fusion and entry depending on their levels of expression. GSLs could act at different steps in the virus 
entry process; i.e., they could stabilize virus binding to the cell surface, or could promote the 
association of CD4/gp120 complexes with co-receptor [97]. Although a role for GSLs in HIV-1 entry 
is compelling, the mechanism underlying the GSL requirement for viral entry remains to be elucidated.  
5.1.3. Role of phospholipids in retrovirus entry  
Phosphatidylserine (PS) is one of the membrane phospholipids that is enriched in HIV-1 virions 
relative to the host cell plasma membrane [36-38]. PS is normally present in the inner leaflet of the 
lipid bilayer; however, during apoptosis, PS is exposed in the outer leaflet [98]. Following infection 
with HIV-1, T cells undergo programmed cell death, resulting in translocation of PS to the outer 
leaflet. Differentiated macrophages, but not monocytes, constitutively express PS in the outer leaflet of 
their plasma membranes [99]. HIV-1 particles produced from macrophages thus incorporate relatively 
high levels of PS in the outer leaflet
 of their envelopes [100]. Recognition
 of PS in the viral envelope 
by macrophages is not required for virus binding; however, PS reportedly stabilizes virus-cell 
interactions, favoring more efficient fusion [100]. Miller and co-workers found that treating cells with 
PS-containing liposomes increased infection by multiple enveloped viruses by up to 20-fold [101,102]. 
Treating with PS-enriched liposomes does not alter receptor levels or Env binding to cells, suggesting 
that PS enhances virus fusion [100]. In some settings, glycosylation of retroviral receptors blocks virus 
entry, apparently serving as a host-cell defense mechanism against retroviral infection [103]. In this 
context, treatment of cells with PS liposomes was observed to overcome the infectivity block [101]. Viruses 2010, 2                               
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Although the mechanism behind this phenomenon awaits clarification, PS treatment does not appear to 
act by altering the glycosylation state of the receptor. Unlike the rapid enhancement in infectivity 
conferred by PS treatment in cells containing functional virus receptors, the effect in cells expressing 
glycosylated receptors occurs with markedly delayed kinetics [101].  
5.2. Lipids in retrovirus assembly 
Retroviral assembly is a multistep process that takes place late in the replication cycle when the 
viral components come together to form a new generation of virus particles (reviewed in [104-106]). 
Replication-competent retroviruses typically encode two membrane-associated structural proteins, the 
Env glycoprotein and the Gag polyprotein precursor. Expression of the Gag precursor alone is 
sufficient to drive the formation of immature virus-like particles (VLPs), whereas for the production of 
infectious particles the Env glycoproteins and pol-coded enzymes PR, RT and IN are also required. 
Assembly takes place in a series of discrete steps and are generally promoted by three functional 
domains within the Gag precursor: the membrane binding (M), Gag-Gag interaction (I), and late (L) 
domains. As mentioned above, abundant evidence supports the idea that retroviral assembly and 
release take place in lipid rafts, consistent with the observation that HIV-1 Gag copatches with the raft 
component GM1 (Figure 5). 
Figure 5. Copatching of HIV-1 Gag proteins with the raft marker GM1. Before fixation, 
Jurkat cells expressing HIV-1 Gag were treated with cholera toxin B subunit to stain GM1. 
Cells were then fixed, permeabilized, and Gag proteins were detected with an anti-p17 MA 
antibody. Gag and GM1 show colocalization, as shown in yellow in the merged image. 
Reprinted with permission from Ono and Freed [1]. Copyright 2005, Elsevier Inc. 
 
 
5.2.1. Role of cholesterol in retrovirus assembly 
The finding that the envelopes of many retroviruses are markedly enriched in cholesterol relative to 
the host cell plasma membrane suggests that retroviral budding takes place in cholesterol-enriched 
membrane microdomains [33,36-38,107,108]. The hypothesis that retroviral assembly takes place in 
lipid rafts is also supported by biochemical analyses showing that the Gag proteins of several Viruses 2010, 2                               
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retroviruses, including HIV-1 [45,46,109-114], MLV [115], and HTLV-1 [116] are associated with 
DRMs. Microdomains containing highly multimerized Gag are likely to be denser than classical lipid 
rafts because of the tight packing of large numbers of Gag molecules [109,111,112]. The exact nature 
of membrane microdomain(s) with which Gag associates, and how Gag binding alters the properties of 
such microdomains, remains to be fully understood.  
There are several motifs in retroviral Gag proteins required for membrane binding and DRM 
association. In the case of HIV-1 and many other retroviruses, the association of the Gag precursor 
with membranes is mediated by a myristic acid moiety covalently linked to the N-terminal Gly of the 
MA domain, and a positively charged cluster of amino acids located near the N-terminus of the MA 
domain. Early reports showed that myristylation of Gag is critical for Gag targeting to membrane, as 
mutating the N-terminal Gly to which the myristate is covalently attached blocks Gag-membrane 
association [117-119]. It was proposed that the membrane binding of Gag is regulated by a myristyl 
switch mechanism, whereby the myristate is in equilibrium between a sequestered and an exposed 
conformation [120,121]. This model is supported by both structural and biochemical evidence   
[122-126]. Summers and co-workers have demonstrated that the myristyl switch is triggered by 
multimerization of Gag [126]. Mutating residues near the N-terminus of MA blocks the myristyl 
switch [122,127]. Pulse-chase analysis suggests that Gag binding to membrane is rapid but DRM 
association is slower, and Gag association with lipid rafts is enhanced or stabilized by Gag-Gag 
interactions [45,112]. Although Gag multimerization appears to stabilize Gag-DRM association, 
studies with an assembly-deficient NC mutant demonstrated that lower-order Gag multimerization is 
sufficient for Gag binding to membrane and DRM [128]. 
The functional relevance of the association of Gag with lipid rafts has been demonstrated by studies 
performed with cholesterol-depleting agents (e.g., BCD), cholesterol biosynthesis inhibitors   
(e.g., statins), cholesterol sequestering agents (e.g., nystatin), and a cholesterol-binding fungal 
antibiotic (AME) [45,46,49,129]. Treating virus-producing cells with these cholesterol-disrupting 
agents impairs HIV-1 particle production [45,46,49,129]. The inhibition of HIV-1 production by 
cholesterol depletion is due to reduced Gag binding to the plasma membrane and defective   
higher-order Gag multimerization [114]. Treating Gag-expressing cells with an unsaturated fatty acid 
that replaces the N-terminal myristate reduces Gag association with DRMs and virus production [130]. 
Feng et al. reported that treating virus-producing cells with -interferon inhibited HTLV-1 assembly 
by preventing Gag association with rafts [116]. These studies indicate that lipid rafts play an important 
role in retroviruses assembly and release. 
The HIV-1 [46,113,131] and MLV [46,68,132] Env glycoproteins are reportedly DRM/lipid raft 
associated. Acylation of proteins, especially involving multiple palmitates, often leads to raft 
association. Although the Env glycoproteins of HIV-1 [131,133-135], MLV [136,137], and RSV [138] 
are palmitoylated, there are contradicting reports in the literature regarding the relationship between 
retroviral Env palmitylation and DRM association. Some studies reported that palmitylation of two 
Cys residues in the gp41 cytoplasmic tail (CT) is required for Env-DRM association [131,133]; other 
reports, however, found that palmitylation is not required for Env-DRM association, Env incorporation 
into virions, or viral infectivity [133,134]. Studies from Clapham’s group showed that Gag-Env 
interactions are required for Env association with lipid rafts, as mutations in MA or the gp41 CT that 
block the putative Gag-gp41 interaction prevent Env association with DRM [139]. Furthermore, these Viruses 2010, 2                               
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authors showed that Gag coexpression is required for DRM association of Env, suggesting that Gag 
recruits Env into rafts [139]. By using protein colocalization and DRM fractionation assays, Nabel and 
co-workers observed that HIV-1 Env and the Ebola glycoprotein localize to distinct domains with 
HIV-1 Gag [140]. Johnson and co-workers using scanning electron microcopy showed that the 
glycoproteins of HIV-1, VSV, and MLV are recruited to budding sites formed by either HIV-1 or RSV 
Gag whereas RSV Env is more selective, exhibiting recruitment only to RSV budding sites [141]. In 
this regard, it has been demonstrated that the CT of gp41 is required for the Env incorporation into 
virions in a number of T-cell lines and primary cell types [142]. Mutating the palmitylation site in 
MLV Env diminishes the association of Env with DRM and significantly reduces Env incorporation 
[132,136]. However, although the palmitylation of Env reduces its expression on the cell surface, 
palmitylation has no significant impact on syncytium formation or virus replication [132,136]. 
Nef, an accessory protein encoded by HIV-1, HIV-2 and SIV, plays an important role in the 
pathogenesis of these primate lentiviruses. The functions of Nef include enhancement of viral 
infectivity and downregulation of CD4 and MHC class I molecules from the surface of infected cells 
[143]. Nef undergoes N-terminal myristylation required for membrane binding and DRM association 
[144,145]. In addition to N-terminal myristylation, basic residues in Nef also contribute to membrane 
binding and raft association [146]. Nef expression has been reported to increase the levels of 
cholesterol and GM1 in virions, perhaps contributing to the enhancement of infectivity induced by Nef 
[145,147]. In macrophages, Nef interacts with ABCA1 (ATP-binding cassette transporter A1) and 
impairs ABCA1-mediated cholesterol efflux, thereby increasing virion cholesterol content and 
infectivity [148]. In contrast to this study, Brugger and colleagues observed that Nef increased SM and 
reduced PC without affecting the levels of cholesterol in virions produced from the MT-4 T-cell line 
[149]. Nef associates with lipid rafts in which kinases like Lck, Fyn and LAT are enriched, and 
stimulates p21-activated kinase (PAK) [144,150]. Fackler and co-workers demonstrated that PAK 
binding and infectivity enhancement require raft association, whereas CD4 downregulation does not; 
nevertheless, membrane binding is required for Nef function [146,150]. In contrast, Schwartz and co-
workers found that not only CD4 downregulation but also viral infectivity is independent of Nef 
association with lipid rafts [151]. The differences in these studies could be attributed to the use of 
different cell types or Nef alleles. Additional studies will be required for a more complete 
understanding of the role of raft association in Nef function. 
Vpu is another accessory protein that associates with membranes, though unlike Nef it is not 
incorporated into viral particles. Vpu significantly enhances HIV-1 release in certain cell types; in 
these cell types, in the absence of Vpu, virions remain tethered to the plasma membrane after 
completion of the budding process [152]. Recent studies have identified CD317/BST-2 (also named 
tetherin) as the host restriction factor that tethers budded virions to the cell surface and is counteracted 
by Vpu [153,154]. It has been observed that tetherin and Vpu are both raft-associated [155a,155b], 
further supporting the concept that HIV-1 assembly takes place in lipid rafts.  
5.2.2. Role of PI(4,5)P2 in retrovirus assembly 
PI(4,5)P2 plays an important role in the association of HIV-1 Gag with the plasma membrane. 
PI(4,5)P2 belongs to the phosphoinositide family of lipids, the members of which differ in the number Viruses 2010, 2                               
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and position of phosphates on their inositol head groups [156]. The different phosphoinositide family 
members are distributed at specific membranes within the cell. For example, PI(3)P is concentrated in 
early endosomes, PI(3,5)P2 is most abundant in late endosomes and PI(4,5)P2 is concentrated primarily 
on the inner leaflet of the plasma membrane [157]. The phosphoinositides help regulate the location of 
a number of cellular proteins; for example, those that contain pleckstrin homology (PH) and epsin  
N-terminal homology (ENTH) domains bind directly to the head-group of PI(4,5)P2 through their 
positively charged cluster of basic amino acids [156]. PI(4,5)P2 levels can be regulated by either 
overexpression of a constitutively active ADP-ribosylation factor 6 (Arf6) mutant, Arf6/Q67L, that 
translocates PI(4,5)P2 from the plasma membrane to PI(4,5)P2-enriched endosomal structures 
[158,159] or by phosphatases such as polyphosphoinositide 5-phosphatase IV (5ptaseIV) that 
hydrolyzes the phosphate at position 5, thereby reducing the levels of PI(4,5)P2 in the plasma 
membrane [160].  
It was proposed that the highly basic domain of the HIV-1 MA domain binds to negatively charged 
lipids in the inner leaflet of the plasma membrane [121,161,162]. Mutating basic residues in the MA 
domain mistargets Gag, such that it associates with internal compartments rather than the plasma 
membrane [122,163-169]. These compartments were defined as late endosomes or MVBs [165]. It was 
shown that overexpression of Arf6/Q67L retargets Gag to PI(4,5)P2-enriched endosomal vesicles, 
whereas overexpression of 5ptaseIV relocalizes Gag from the plasma membrane to late 
endosmes/MVBs [170,171]. In both cases, due to retargeting of Gag, HIV-1 release is severely 
reduced. These findings demonstrated that PI(4,5)P2 in the plasma membrane is required for efficient 
HIV-1 release.  
Several groups, using different approaches, have demonstrated a direct interaction between MA and 
PI(4,5)P2 [38,124,170,172]. Summers and co-workers used nuclear magnetic resonance (NMR) 
spectroscopy to solve the structure of a complex between myristylated MA and a soluble derivative of 
PI(4,5)P2 [124,173]. This study suggested that besides electrostatic interactions between the negatively 
charged headgroup of PI(4,5)P2 and basic residues in MA, the 2’-unsaturated acyl chain of PI(4,5)P2 
binds to a hydrophobic cleft within the globular core of MA (Figure 6) [124,173]. The extrusion of the 
unsaturated acyl chain from the lipid bilayer upon Gag binding could promote the partitioning of Gag 
to the more saturated lipid raft microenvironment [124]. Furthermore, these NMR data also suggested 
that PI(4,5)P2 binding to MA triggers the myristyl switch, leading to myristate exposure. Thus, 
according to this model, PI(4,5)P2 acts as both a membrane anchor and a trigger for myristate 
exposure. Shkriabai et al.  used mass spectrometric protein footprinting analysis with a lysine-
modifying agent to identify MA residues 29 and 31 as being important for the MA-PI(4,5)P2 
interaction [172]. Notably, mutation of these basic residues mistargets Gag and virus assembly to 
MVBs [165,167,174,175]. Ono’s group used liposome-binding assays to show that full-length 
myristylated Gag binds to PI(4,5)P2-enriched vesicles, and the residue 29/31 mutant showed reduced 
PI(4,5)P2-dependent liposome binding, again highlighting the importance of these residues in the   
Gag-PI(4,5)P2 interaction [170]. Chan et al. reported that HIV-1 and MLV virions are enriched in 
PI(4,5)P2 relative to the plasma membrane, and mutating the basic residues in MA significantly 
reduced the incorporation of PI(4,5)P2 into particles [38]. These observations suggest that MA interacts 
with PI(4,5)P2 not only in vitro but also in cells. Direct binding of PI(4,5)P2 is also reported for other 
retroviruses, e.g., HIV-2 [176], EIAV [177], and MLV [178]. Barklis and co-workers recently reported Viruses 2010, 2                               
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that myristylated MA organizes into hexameric rings of trimers on artificial membranes containing 
60% PC, 20% PI(4,5)P2, and 20% cholesterol [179]. Interestingly, cholesterol was observed to enhance 
the selectivity of MA for PI(4,5)P2 in this in vitro system. Collectively, these studies demonstrate that 
diverse retroviruses exploit MA-PI(4,5)P2 interactions for Gag trafficking and virus release.  
Figure 6. Complex between HIV-1 MA and PI(4,5)P2. The highly basic surface of MA 
(blue) exhibits electrostatic interactions with PI(4,5)P2 (yellow and red phosphates). The 
2’-unsaturated acyl chain of PI(4,5)P2 (yellow) binds to the hydrophobic cleft in MA and 
the myristyl group (green) of MA inserts into the lipid bilayer. Unpublished image 
provided by Dr. M. Summers, based on the data of Saad et al. [124]. 
 
 
5.3. Lipids in cell-cell transmission 
While most enveloped viruses can infect their target cells as free virions (cell-free infection), in 
many cases cell-cell transfer is a more efficient mode of virus spread [180-182]. Cell-free infection 
faces many obstacles, including antibody-mediated neutralization, innate cellular defenses, particle 
degradation, low target-cell binding efficiency, and the need for virions to diffuse over long distances 
[182]. Virus transmission directly from infected to uninfected cells can avoid many of these obstacles, 
thereby increasing the efficiency of virus spread [180,182,183]. A number of studies have Viruses 2010, 2                               
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demonstrated that retroviruses spread via cell-cell transmission at intercellular contacts known as 
virological or infectious synapses [174,184-190], which appear to mimic the immunological synapse. 
The virological synapse, in the case of HIV-1, is formed between the viral Env of the infected cell 
(effector) and the receptors (CD4, CXCR4/CCR5) on the uninfected (target) cells resulting in lipid 
raft-like patches on the effector cells (Figure 7) [187,191]. Interestingly, some viruses such as HTLV-1 
spread within and between host cells almost entirely by cell-cell transfer because released particles are 
in general poorly infectious as cell-free virions [192]. Cell-cell transmission is also reported for 
retroviruses such as HIV-1 [187,189,193] and MLV [194]. Env-receptor interactions appear to be 
important for synapse formation in some systems, e.g., HIV-1 transfer between T-cells [188] and 
transfer of MLV across filopodial bridges [194]; however, Env expression is not required for 
recruitment of Gag to the macrophage-T-cell or macrophage-macrophage synapse [174]. 
Figure 7. Virological synapse showing HIV-1 Gag and Env concentrating in a raft-rich 
domain. Primary CD4
+ T-cells (top) were incubated with HIV-1-infected Jurkat cells 
(bottom) for 1 h at 37 
oC. During the incubation, cells were stained for Env (red), fixed and 
stained with cholera toxin B subunit (green), specific for the raft marker GM1. Cells were 
permeabilized and Gag proteins were detected with anti-p17 antibody (blue). Images were 
superimposed; white indicates the colocalization of three colors. Reprinted with permission 
from Jolly and Sattentau [191]. Copyright 2005, The American Society of Microbiology. 
 
 
There is accumulating evidence suggesting that the anchoring of filopodia is a prerequisite for the 
formation of cell-cell interfaces and virological synapses [194-196]. It has been reported that HIV-1 
and MLV can drive the formation of filopodia through Env-receptor interactions, then virus particles 
‘surf’ on the filopodia towards the uninfected target cell body, where virus-cell fusion occurs in a Viruses 2010, 2                               
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receptor-dependent manner [194,195]. HIV-1 transmission between T-cells may occur on   
actin-containing membrane nanotubes that physically connect two or more T-cells over a long 
distance; the speed with which HIV-1 particles travel between cells is suggestive of actin-mediated 
transport [196].  
It is well established that immunological synapses exhibit raft-like properties [197], and as 
discussed above, HIV-1 particles enter in and bud from lipid-raft microdomains. It is thus likely that 
lipid rafts play a role in the formation of virological synapses. Indeed, Sattentau and co-workers found 
that Env colocalizes with the raft markers GM1 and CD59 at the T-cell synapse in effector cells [191]. 
Upon conjugation of effector and target cells, within one hour HIV-1 Gag and Env in the effector cell 
and CD4 in the target cell copolarize to the site of GM1 enrichment. Furthermore, patches of Env and 
GM1 are also observed on the target cell membrane, suggesting that the fusion of virions with 
receptors in target cells occur at the virological synapse. Interestingly, upon treating the effector cells 
with BCD prior to synapse formation, GM1 staining in the effector cells is dispersed, and CD4 
polarization in the target cells is prevented [191]. Polarization of Gag and Env to the synapse in the 
effector cell is also prevented by cholesterol depletion. Derse and co-workers reported that HTLV-1 
Gag colocalizes with CD82 and other tetraspanins at the plasma membrane of T-cells, and upon   
cross-linking with CD82 antibody Gag and CD82 rapidly segregate to patches [198]. Upon cholesterol 
depletion with BCD, HTLV-1 Gag and CD82 do not segregate efficiently on the cell surface [198]. 
These studies demonstrate that cholesterol plays an important role in cell-cell virus transmission at the 
synapse.  
6. Lipid-modifying agents as inhibitors of retroviral replication 
6.1. Cholesterol modifying agents 
The studies mentioned above reveal the importance of cholesterol in both early and late phases of 
the virus replication cycle. Modifying the cholesterol content of the virions or target cells inhibits  
HIV-1 infection [40-42,52,53,55,199,200] and depleting cholesterol from virus-producing cells with 
BCD or statins inhibits the production of viral particles and the infectivity of the released virions 
[45,46]. Recent studies from our lab demonstrate that not only cholesterol-depleting agents, but also 
cholesterol-binding compounds such as AME, have a profound effect on both viral entry and particle 
production [49,129]. As a result, the replication of HIV-1 and SIVmac239 is inhibited by the presence 
of AME [49-51]. Truncating the long CT of either HIV-1 or SIVmac gp41 renders the infectivity of 
virions bearing the truncated Env glycoproteins resistant to AME. Likewise, virions bearing foreign 
viral glycoproteins from either MLV or VSV are also unaffected by AME in single-cycle infectivity 
assays. Thus, the presumed binding of AME to cholesterol in the viral envelope blocks particle 
infectivity in a manner that is specific to virions bearing the full-length HIV-1 Env glycoprotein 
complex. Incorporation of AME into the viral envelope may perturb membrane fluidity such that the 
fusogenicity of the full-length Env glycoprotein in suppressed. Interestingly, single-amino-acid 
substitutions in the HIV-1 gp41 CT confer resistance to this cholesterol-binding compound [49-51]. 
These mutations create a cleavage site in the gp41 CT for the viral PR, rendering the virus   Viruses 2010, 2                               
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AME-resistant. The inhibitory effect on the release of HIV-1 by AME may be due to impaired ability 
of the HIV-1 accessory protein Vpu to enhance virus release [129]. 
The requirement for cholesterol at multiple steps in the HIV-1 replication cycle raises the possibility 
that cholesterol-depleting or binding agents could potentially offer new approaches to the development 
of antiviral agents. Statins, which block cholesterol biosynthesis by inhibiting the enzyme HMG-CoA 
reductase, were examined for antiviral activity in vivo in several studies [201-205]. 2-hydroxypropyl-
-cyclodextrin (2OHpßCD) inhibited vaginal transmission of HIV-1 and lovastatin decreased HIV-1 
replication in humanized murine model systems [201,202]. Manes and co-workers reported that 
lovastatin decreased viral loads
 and increased CD4
+ cell counts in HIV-1-infected patients [201]. This 
inhibition is due to down-regulation of Rho GTPase activity by reducing its geranylgeranylation [201]. 
Inhibition of viral entry and budding in statin-treated cells was reversed by the addition of   
L-mevalonate or geranylgeranylpyrophosphate,
 but not by cholesterol. They concluded that the anti-
HIV-1 activity conferred by statins is due to inhibition of Rho GTPase activity. In contrast to this 
report, several other independent studies failed to confirm the antiviral activity of statins in vivo   
[203-205]. Interestingly, Rugeles and co-workers recently showed that in chronically infected 
individuals lovastatin may display anti-HIV-1 activity [206].  
While systemic treatment with drugs that target cholesterol are unlikely to consistently reduce viral 
loads at subtoxic concentrations, use as chemopreventive agents (“topical microbicides”) may hold 
more promise. As mentioned above, Markham and co-workers used SCID mice carrying human 
peripheral blood leukocytes (Hu-PBL-SCID) in which cell-associated HIV-1, but not cell-free virus, 
was efficiently transmitted by vaginal inoculation of HIV-1 infected cells [202]. They found that 
topical application of 2OHpßCD to vaginal mucosa prior to inoculation with HIV-1-infected cells 
blocks transmission of cell-associated HIV-1 without damaging the vaginal epithelial cell membrane.  
Lee and co-workers recently reported that an aryl methyldiene rhodanine derivative that intercalates 
into viral membranes inhibits the infectivity of a wide variety of enveloped viruses. The mechanism of 
inhibition, however, remains to be defined [207]. 
6.2. Sphingolipid synthesis inhibitors 
Several lines of evidence support the concept that sphingolipids play a direct and/or auxiliary role 
during HIV-1 infection. Although the exact mechanism of action of sphingolipids in HIV-1 infection 
needs further investigation, these lipids act at the level of virus fusion with their target cells. A number 
of strategies have been developed to manipulate the levels of sphingolipids or sphingolipid-based 
molecules to inhibit HIV-1 infection. The levels of sphingolipid can be modulated by inhibiting their 
biosynthesis at various intermediate steps; for example, L-cycloserine and fumonisin B1 inhibit the 
activity of serine palmitoyltransferase and dihydroceramide synthase, respectively [89]. L-cycloserine 
inhibits HIV-1 replication by reducing virion infectivity [208], perhaps in part by down-modulating 
CD4 expression [209]. The infectivity of virions produced from fumonisin B1-treated MT-4 cells was 
reduced significantly [37]. Sphingolipids in the viral membrane may play a role in the transfer of  
HIV-1 mediated by dendritic cells, as virions produced from fumonisin B1-treated cells were 
inefficiently captured by both immature and mature dendritic cells [210]. PPMP has been shown to 
block HIV-1 infection in primary T-cells and in various cell lines expressing CD4, CXCR4, and/or Viruses 2010, 2                               
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CCR5 by blocking Env-mediated plasma membrane fusion and entry [87,90]. While   
N-butyldeoxynojirimycin inhibits HIV-1 entry, potentially by affecting gp41 exposure [211,212], this 
compound did not demonstrate efficacy in clinical trials [213]. Metabolites of GSLs such as ceramide, 
and modified GSLs that preferentially partition into membrane microdomains, were also tested for 
antiviral activity (reviewed in [89]). Finnegan et al. reported that ceramide upregulation in target cells 
by pharmacological agents such as N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), treating cells 
with SMase, or exogenous addition of long-chain ceramide, can modulate HIV-1 entry [93]. 
Upregulation of ceramide influences the biophysical properties of the plasma membrane and can 
initiate various physiological responses such as apoptosis [214]. Kensinger et al. synthesized a series 
of GalCer and SGalCer-derived dendrimers, which mimic the carbohydrate clustering reportedly found 
in lipid rafts, and one such dentrimer, PS Gal 64mer, inhibited HIV-1 infection [215]. Vierling and 
coworkers reported that a bipharmacophore that combines the bicyclam AMD3100 and a GalCer 
analog inhibits HIV-1 replication [216]. Lingwood and colleagues showed that adamantlyGb3, a 
globotriaosylceramide analog, was able to prevent virus-cell fusion irrespective of HIV strain or 
chemokine co-receptor preference [217]. These studies suggest that GSL analogs compete with   
HIV-GSL interactions and inhibit HIV-1 infection [218-220]. If toxicity could be minimized, these 
compounds might potentially offer novel approaches to antiviral therapy.  
7. Conclusions and perspectives 
It is evident that lipids such as cholesterol and sphingolipids, and membrane microdomains enriched 
with these lipids, play important roles in both early and late steps in the replication of a large number 
of enveloped viruses. The involvement of lipid microdomains in retrovirus replication is defined by the 
association of viral proteins (e.g., Gag, Env, Nef, Vpu), and their cellular partners (e.g., CD4, CCR5, 
CXCR4, tetherin) with these microdomains. Despite compelling experimental support for the 
involvement of lipid rafts in retroviral replication, additional information is needed to elucidate the 
mechanistic basis by which these membrane microdomains promote virus replication. More detailed 
studies using advanced techniques such as FRET, FRAP, SPT by high-resolution video microscopy, 
IEM, two-photon microcopy, etc., will be useful to obtain further insights. Although the role of lipid 
microdomains in enveloped virus replication is well established, there are currently no FDA-approved 
drugs targeting viral lipid envelopes available for the treatment of diseases caused by enveloped 
viruses. As with all drugs that target host-derived components, adverse side effects of lipid-based 
drugs are a primary concern. Nevertheless, a more in-depth understanding of the role of lipid 
microdomains in retroviral replication will not only increase our basic understanding of these 
important human pathogens, but may also suggest novel approaches for pharmacological intervention.  
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